EIKO

EIKO LIFESCIENCES financials

Market cap
₹71 Cr

Quarterly results

Q1 FY27: revenue up 56.4%, net profit up 36.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue8 7 11 11 12 +43%12 +60%18 +63%17 +56%
EBITDA0 1 1 2 2 +312%2 +198%2 +71%2 +28%
Net profit0 0 1 1 1 +361%1 +240%2 +20%2 +36%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −12.6% 1Y

₹45.0₹50.0₹55.0₹60.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹52.49 on 9 Sept 2025 → ₹45.9. High ₹62.03 (4 Nov 2025), low ₹45.38 (4 Sept 2026).

Financials, as filed

Revenue grew 125.6% a year over 2 years, FY20 to FY26. Operating margin widened to 14.1%.

Year endingFY20FY25FY26
Revenue₹10 Cr₹38 Cr₹53 Cr
Operating profit₹-5 Cr₹3 Cr₹7 Cr
Operating margin-44.0%7.4%14.1%
Interest₹0 Cr₹0 Cr₹0 Cr
Depreciation₹0 Cr₹1 Cr₹1 Cr
Net profit₹-4 Cr₹2 Cr₹5 Cr
Net margin-35.0%6.2%10.1%
Cash from operations₹-0 Cr₹3 Cr₹2 Cr
Free cash flow₹-1 Cr₹-8 Cr₹2 Cr
ROCE-105.4%11.1%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY18FY19FY20FY25FY26
Equity capital₹4 Cr₹4 Cr₹4 Cr₹14 Cr₹14 Cr
Reserves₹2 Cr₹1 Cr₹-1 Cr₹45 Cr₹54 Cr
Borrowings₹2 Cr₹1 Cr₹2 Cr₹1 Cr₹5 Cr
Other liabilities₹4 Cr₹3 Cr₹7 Cr₹5 Cr₹16 Cr
Total liabilities₹11 Cr₹9 Cr₹12 Cr₹65 Cr₹89 Cr
Fixed assets₹2 Cr₹2 Cr₹2 Cr₹23 Cr₹22 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹3 Cr₹2 Cr₹0 Cr₹7 Cr₹15 Cr
Other assets₹6 Cr₹6 Cr₹10 Cr₹35 Cr₹52 Cr
Total assets₹11 Cr₹9 Cr₹12 Cr₹65 Cr₹89 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters added +3.17 pp while the public trimmed −3.17 pp. The shareholder count shrank 9% to 3,019.

Promoters
39.9%
Public
60.1%

Since Jun 2025

  • Promoters +3.17 pp
  • Public −3.17 pp

How it drifted, 12 quarters

Over this window promoters went from 24.2% to 39.9% — +15.7 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 24.2%, Public 75.8%.Dec '23: Promoters 24.2%, Public 75.8%.Mar '24: Promoters 24.2%, Public 75.8%.Jun '24: Promoters 24.4%, Public 75.6%.Sep '24: Promoters 24.4%, Public 75.6%.Dec '24: Promoters 31.3%, Public 68.7%.Mar '25: Promoters 36.2%, Public 63.8%.Jun '25: Promoters 36.7%, Public 63.3%.Sep '25: Promoters 37.2%, Public 62.8%.Dec '25: Promoters 37.2%, Public 62.8%.Mar '26: Promoters 39.9%, Public 60.1%.Jun '26: Promoters 39.9%, Public 60.1%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of EIKO LIFESCIENCES LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Lenus Finvest Private Limited 17.71%unchanged
Laxmikant Kabra (Huf) 9.90%unchanged
2B Black Bio Llp 9.66%unchanged
Bhavesh Dhirajlal Tanna 5.86%unchanged
Siddhant Laxmikant Kabra 5.63%unchanged
Ashika Global Finance Private Limited 4.19%+0.06 pp
Ashok Vishwanath Hiremath 3.72%unchanged
Sushila Paraskumar Daga 2.78%+1.12 pp
Sivanesan Sellappan 2.02%unchanged
Joyanta Kumar Jana 1.99%unchanged
Parshva Kumar Daga 1.68%unchanged
Bhavinkumar Vinaychand Shah 1.35%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.